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 FUNCTIONAL ANALYSIS OF THE MURINE OLIGOADENYLATE  
 












 The flavivirus resistance gene, Flv, in mice has been identified as 2′-5′ 
oligoadenylate synthetase 1b (Oas1b).  Susceptible mice produce a protein that is 
truncated (Oas1btr) at the C-terminus due to a premature stop codon encoded by a C820T 
transition.  Mice produce 8 Oas1 proteins, Oas1a-Oas1h.  In the present study, Oas1a, 
Oas1b and Oas1btr were expressed as MBP-fusion proteins in bacteria and purified.  2-
5A synthetase activity was demonstrated using MBP-Oas1a, while neither MBP-Oas1b 
nor MBP-Oas1btr were functionally active.  The 2-5A synthetase activity of MBP-Oas1a 
was inhibited in a dose-dependent manner by the addition of MBP-Oas1b but not MBP-
Oas1btr.  Finally, three RNA probes were synthesized from the 3′ end of the WNV 
Eg101 genome and used to test the ability of the expressed Oas1 proteins to bind to viral 
RNA.  Results of the RNA binding activity assays suggest Oas1 proteins may specifically 
interact with regions of WNV RNA. 
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FUNCTIONAL ANALYSIS OF THE MURINE OLIGOADENYLATE 
SYNTHETASE 1b (Oas1b) 
 
INTRODUCTION 
General Characteristics of Flaviviruses 
 Previously part of the family Togaviridae, flaviviruses and pestiviruses were 
reclassified as part of an evolutionarily distinct family, Flaviviridae.  The family 
Flaviviridae consists of three genera: the flaviviruses, the pestiviruses and the 
hepaciviruses.  In addition to these genera, GB viruses have been assigned to the 
Flaviviridae family, but are not yet a genus.  Flaviviridae belong to the positive-strand 
RNA virus supergroup 2, which encode similar RNA-dependant RNA polymerases 
(RdRp) (Lindenbach and Rice, 2001).  Members of the family Flaviviridae share a 
common gene order, replication strategy, and all lack a 3′ poly (A) tail. 
The genus flavivirus currently contains ~70 viruses that are divided into 12 
serogroups (Heinz et al., 2000), and includes a number of important human pathogens, 
such as yellow fever virus (YFV), dengue virus (DV), Japanese encephalitis virus (JEV), 
Murray Valley encephalitis virus (MVEV), St. Louis encephalitis virus (SLEV), West 
Nile virus (WNV), and tick-borne encephalitis (TBE).  The JEV serocomplex includes 
JEV, MVEV, SLEV, WNV, Usutu virus, and Yaounde virus (Poidinger et al., 1996).  
Many flaviviruses are transmitted between vertebrate hosts by mosquitos or ticks, and as 
such, they are called “arboviruses” or arthropod-borne viruses.  Approximately 50% of 
flaviviruses are transmitted by mosquitos and 28% by ticks.  No known arthropod vector 
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has been identified for the remaining 22%, and they may be transmitted by rodent or bats 
(Rice, 1996; Porterfield, 1996).  WNV is a mosquito-borne virus that primarily infects 
birds but can also infect humans (Bernard et al., 2001).  West Nile virus was first isolated 
in Uganda in 1937 (Smithburn et al., 1940).  WNV has been endemic in the Middle East, 
Africa, and western Asia; however, WNV recently expanded its geographical distribution 
to the Western hemisphere (CDC, 2003; Petersen and Roehrig, 2001).   
The flavivirus genome is a single-stranded RNA of positive polarity that is 
involved in at least three cytoplasmic processes upon infection of the host cell:  it acts as 
an mRNA that is used to synthesize viral proteins, it serves as a template for RNA 
replication, and it is targeted along with structural proteins for packaging into virions 
(Lindenbach and Rice, 2001).  The flavivirus RNA genome contains a type I cap 
(m7GppAMP) at the 5′ terminus and is the only animal RNA virus that lacks a 3′ poly (A) 
tail.  The genomic RNA of flaviviruses encodes a single open reading frame (ORF) that is 
flanked by 5′ and 3′ untranslated regions (UTR) of about 100 and 600 nucleotides, 
respectively (Rice, 2001).  At the end of the 3′ UTR is a stem-loop structure that is 
absolutely required for viral replication and is highly conserved among divergent 
flaviviruses.  A putative cyclization sequence in the 3′ UTR as well as its complementary 
sequence in the capsid coding region of the 5′ end of the genome are present in the 
genomes of all mosquito-borne flaviviruses (Brinton et al., 1986, You et al., 2001).  A 
single polyprotein precursor is translated from the large ORF.  The viral polyprotein is 
proteolytically processed by the viral serine protease (NS2B-NS3) and host cellular 
proteases to produce ten mature viral proteins.  Three viral structural proteins, capsid (C), 
membrane (prM/M), and envelope (E) are encoded within the 5′ part of the viral RNA 
3 
genome, while the 3′ portion of the genomic RNA encodes 7 nonstructural proteins (NS1, 
NS2A, NS2B, NS3, NS4A, NS4B, and NS5) (Rice et al., 1985).     
 
Molecular Biology of Flaviviruses 
 The flavivirus particle is small, spherical, and ~50 nm in diameter with an 
electron-dense ribonucleoprotein core ranging from 20 to 30 nm in diameter.  A host-
derived lipid envelope surrounds the flavivirus particle (Murphy, 1980).  Three viral 
structural proteins are associated with the virion:  the E, prM/M, and C proteins 
(Lindenbach and Rice, 2003).  The mature C protein (~11 kDa) is thought to interact with 
viral genomic RNA in the cytoplasm to form a nucleocapsid precursor (Lindenbach and 
Rice, 2003); the charged residues at the N- and C- termini of the C protein presumably 
mediate these interactions (Khromykh and Westaway, 1996).  The precursor of C, 
anchored C, is cleaved at its C-terminus by the viral serine protease; the C-terminal 
hydrophobic domain of C mediates translocation of prM to the ER prior to cleavage 
(Amberg et al., 1994; Lobigs, 1993; Yamshchikov and Compans, 1994).  The M protein 
(~8 kDa) is a proteolytic fragment of its glycoprotein precursor, prM protein (~26 kDa).  
Late in virus maturation, during egress of the virion, prM is cleaved into mature M 
protein in the Golgi-network by furin, a convertase enzyme (Stadler et al., 1997).  The 
major virion surface protein is the E protein, a glycosylated type I integral membrane 
protein that is ~53 kDa in size.  In mature virions, E protein homodimers are arranged in 
a head-to-tail conformation and lie parallel to the lipid bilayer (Heinz and Allison, 2000).  
The E protein also forms heterodimers with prM, maintaining the E protein in a fusion-
inactive conformation until virion maturation via prM cleavage and release from the cell 
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(Heinz and Allison, 2000). The E protein is a major antigenic determinant on the surface 
of flavivirus particles; it mediates cell-receptor binding and fusion during entry of the 
viral particle into the host cell, (Linderbach and Rice, 2003).  
 Although the complete mechanism for the formation of viral RNA replication 
complexes has yet to be elucidated, interactions between viral nonstructural proteins and 
between host cell proteins and the viral proteins may be required (Brinton, 2002).  NS1 is 
translocated to the ER and is subsequently released from the E protein by cleavage of a 
signal sequence recognized by a signalase (Chambers et al., 1995).  The eight C-terminal 
residues of NS1 and ~140 N-terminal residues of NS2A are required for the cleavage of 
NS1 from NS2A by an unknown host protease (Chambers et al., 1990; Hori and Lai, 
1990; Falgout and Markoff, 1995; Pethel et al., 1992).  Although mutations that prevent 
cleavage at the NS1/NS2A junction have proven lethal, it is unclear what other functions 
are carried out by NS2A (Lindenbach and Rice, 2003).  NS2B is a membrane associated 
protein that is required as a cofactor for the activity of the serine protease of NS3 which 
cleaves at multiple sites in the viral polyprotein (Chambers et al, 1991, 1993).  The NS3 
sequence is highly conserved among flaviviruses.  Based on data demonstrating RNA-
stimulated NTPase activity for the JEV NS3 (Kuo et al., 1999; Wengler and Wengler, 
1991), and RNA helicase activity for the dengue 2 NS3 (Li et al., 1999), it seems likely 
that NS3 is also involved in RNA replication.  NS5 is the viral RNA-dependent RNA 
polymerase and is the most conserved flavivirus protein.  NS5 also contains a 
methyltransferase domain that may be involved in methylation of the 5′ cap structure of 
the genomic RNA (Lindenbach and Rice, 2003; Koonin, 1993).  Little is known about the 
roles of NS4A and NS4B; although, recent studies have suggested that they may play a 
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role in evading the host antiviral response by inhibition of interferon (IFN) signaling 
(Munoz-Jordan et al., 2003; Lin et al., 2004; Liu et al., 2004; Liu et al., 2005).  For 
instance, Munoz-Jordan et al. (2005) suggested that the expression of NS4B of dengue-2 
resulted in inhibition of signal transducers and activators of transcription-1 (STAT1) 
nuclear translocation in response to IFN thereby blocking the IFN signaling cascade, and 
that posttranslational cleavage of NS4A/NS4B by the viral protease NS3 is a prerequisite 
for their IFN-antagonistic properties.  JEV infection blocks tyrosine phosphorylation of 
the cellular kinase, Tyk2, which is essential for IFN signaling (Lin et al., 2004).  Several 
nonstructural proteins of WNV, including NS4B have been shown to inhibit STAT1/2 
phosphorylation (Liu et al., 2005).  West Nile virus replication prevented activation of 
Tyk2 and janus protein tyrosine kinase-1 (JAK) and therefore inhibited the signaling 
mediated by IFN-α (Guo et al., 2005). 
While only short regions within the 5′ UTR sequence are conserved among 
different flaviviruses, the 5′-terminal structure it forms shares structural homology 
between different flaviviruses (Brinton and Dispoto, 1988).  The 3′ UTR of the minus-
strand, which is the site of initiation of plus-strand synthesis, is complementary to the 5′ 
UTR.  Deletions in the 5′ UTR of the plus-strand proved lethal for dengue 4 replication 
(Cahour et al., 1995).  Shi et al. (1996) detected 4 cell proteins in WNV-infected hamster 
cells that bind to a probe comprised of the 3′ UTR of the minus-strand of WNV; TIAR 
and TIA-1 were subsequently identified as 2 proteins that bound to this region of WNV 
(Li et al, 2002).  Similarly to the 5′ UTR, the flavivirus 3′ UTR contains only a few 
conserved sequences (Lindenbach and Rice, 2003).  However, a 3′ stem-loop (3′ SL) 
consisting of 90 to 120 nucleotides forms a structure that is highly conserved among 
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divergent flaviviruses (Brinton, 1986).  Specific interactions of 3 hamster cell proteins, 
one of which was subsequently identified as translation elongation factor 1A (EF1A), 
with the 3′ SL of WNV RNA were reported (Blackwell and Brinton, 1995; Blackwell and 
Brinton, 1997). 
Flaviviruses enter the host cell by receptor-mediated endocytosis after binding of 
the viral E protein to an unknown cell-surface receptor(s).  Following cell entry, low-pH 
induces fusion of virion envelops to host cell vesicle membranes in prelysosomal 
endocytic compartments releasing the viral nucleocapsid into the cytoplasm where the 
genomic RNA is uncoated by an unknown process (Lindenbach and Rice, 2003).   
Flavivirus infection causes significant rearrangement and proliferation of cytoplasmic, 
perinuclear endoplasmic reticular (ER) membranes (Brinton, 2002; Lindenbach and Rice, 
2003; Knipe and Howley, 2001).  The genomic RNA is translated into a single 
polyprotein that is cleaved at various sites by host and viral proteases to produce 
structural and nonstructural viral proteins (Heinz et al., 1994).   
Replication of the viral RNA is thought to occur in smooth membrane vesicle 
clusters.  However, these vesicle packets have only been observed late during infection 
(Mackenzie et al., 1999); thus, the site of the early events of replication is still unknown.  
Viral RNA replication begins by synthesis of a genome-length minus-strand RNA.  The 
duplex formed by viral minus- and plus-strand RNAs has been termed the replicative 
form (RF); this RF is thought to serve as a template for synthesis of genomic RNA.  The 
replicative intermediate (RI) contains both single and double stranded regions, 
presumably consisting of the minus-strand RNA template and nascent plus-strand RNAs 
of different lengths generated by reinitiation; this allows more than one plus-strand RNA 
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to be synthesized from a single minus-strand RNA at a time (Baltimore et al., 1968; 
Wengler et al., 1978; Cleaves and Dubin, 1979; Cleaves et al., 1981; Chu and Westaway, 
1985).  Although negative-strands continuously accumulate during infection, they have 
been isolated in double-stranded forms only (Cleaves et al., 1981; Wengler et al., 1978).  
The observed 10- to 100-fold excess of viral plus-strand RNAs over negative-strand 
RNAs in infected cells has been attributed to a semiconservative and asymmetric mode of 
replication (Cleaves et al., 1981; Chu and Westaway, 1985).  Little is known about viral 
packaging and release, although viral assembly occurs in association with rough ER 
membranes (Lindenbach and Rice, 2003).  Accumulation of intracellular immature 
virions in vesicles is followed by transport through the host secretory pathway where the 
N-terminal portion of prM is cleaved in the Golgi-apparatus (Wengler, 1989; Stadler et 
al., 1997).  As the new virions are transported to the plasma membrane in vesicles, they 
are released by exocytosis (Mason, 1989). 
 
Genetic resistance to flavivirus-induced disease 
 Interactions between host-specific factors and viral components influence the 
course and outcome of flaviviral infections (Bang, 1978).  Observations of flavivirus 
infections in horses, birds, rodents, humans, and non-human primates, suggest an innate 
resistance to flavivirus-induced disease in some individuals from a number of species 
(Shellam et al., 1998). Horses infected with WNV showed differential susceptibility to 
WNV-induced disease (Bunning et al., 2002; Durand et al. 2000).  Challenge of 4 species 
of grouse with louping ill (LI) virus (a flavivirus) showed that three of the species (red 
grouse, willow grouse, and ptarmigan) developed high levels of viremia and died.  The 
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fourth species (capercaillie) had very low levels of viremia and survived (Reid et al., 
1980).  Similarly, yellow fever virus infection has been shown to be clinically mild in 
African species of monkeys, while usually deadly in South American species of monkeys 
(Shellam et al., 1998; Bauer and Mahaffy, 1930; Smithburn and Haddow, 1949).  
Observations during two dengue virus epidemics in Cuba in 1981 and 1997 showed that 
fewer blacks were hospitalized with dengue hemorrhagic fever/dengue shock syndrome 
than whites suggesting the presence of a dengue resistance gene and that more blacks 
than whites carried the resistant allele(s) (Kouri et al., 1987; Kouri et al., 1989; Guzman 
et al., 1990).  In 2002 in the Chicago area, 52 % of the population consisted of white 
individuals but whites accounted for ~83 % of the individuals showing symptoms of 
WNV-induced disease (Ruiz et al., 2004).  Although no resistance gene against 
flavivirus-induced has yet been found in humans yet, a single gene in mice (Flv) has been 
shown to affect the levels of virus production and the severity and outcome of disease 
caused by flaviviruses (reviewed in Brinton, 1986). 
 
Murine resistance to flavivirus-induced disease 
 Leslie Webster, in the 1920’s, established strains of mice that were either resistant 
or susceptible to paratyphoid (bacterial) infection through selective breeding (Webster, 
1923).  Mouse strains resistant and susceptible to louping ill virus were also established 
(Webster, 1933).  Independent segregation of bacterial and viral resistance was 
demonstrated by establishment of mouse strains that showed resistance to only one type 
of infection, either paratyphoid or louping ill virus infection but not both.  Resistant mice 
that survived louping ill virus challenge were later shown to be resistance to SLEV, a 
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mosquito-borne virus, and Russian spring-summer virus, a tick-borne virus (Webster, 
1937; Casals and Schnider, 1943).  Subsequently, infection of the mice with a number of 
different viruses showed that although resistance was conferred against both mosquito- 
and tick-borne flaviviruses, resistance did not extend to other types of viruses (Brinton 
and Perelygin, 2003; and references therein).  Monogenic, autosomal inheritance was 
shown for the flavivirus resistance phenotype (Sabin, 1952).  Production of a congenic 
flavivirus-resistant C3H/RV strain was accomplished by the introduction of the resistance 
gene carried by PRI mice into the flavivirus-susceptible C3H/He strain (Groschel and 
Koprowski, 1965).  The C3H/RV strain was subsequently renamed C3H.PRI.Flvr 
(Urosevic et al., 1999).   
Although resistant mice are resistant to disease induced by all flaviviruses tested, 
they are susceptible to flavivirus infection.  A number of factors such as route of 
inoculation, dose and virulence of the infecting virus can all influence the outcome of 
flavivirus infection in mice.  For instance, C3H.PRI.Flvr mice show complete resistance 
to intracerebral inoculation of YFV-17D vaccine, whereas intracerebral inoculation by 
the more virulent WNV can kill the resistant mice.  Nevertheless, intracerebral 
inoculation with 50,000 PFU of WNV resulted in 33 % mortality in resistant mice, 
compared to 82 % mortality in susceptible ones after a 5,000 PFU intracerebral 
inoculation of WNV (Brinton Darnell et al., 1974).  Intraperitoneal injection of 108.5 PFU 
WNV did not cause disease in resistant mice, while 50 % mortality was achieved in 
susceptible mice after injection of 107.5 PFU of WNV intraperitoneally (Brinton, 1986).  
Resistant mice produced much lower titers of flavivirus, and showed a slower spread of 
infection as compared to congenic susceptible C3H/He mice (Shellam et al., 1998; 
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Goodman and Koprowski, 1962; Brinton Darnell et al., 1974; Brinton Darnell and 
Koprowski, 1974; Webster and Johnson, 1941; Vainio, 1963).  Henson et al. (1969) 
demonstrated that peak brain titers are 10,000 fold lower in resistant mice compared to 
susceptible mice after a 105.5 PFU intracerebral inoculation of WNV; and that peak titers 
were observed by day 3, with death on day 4, in susceptible mice and day 4, with death 
on day 7 or 8 in resistant mice.   
Intraperitoneal challenge with Banzi virus was lethal in C3H.PRI.Flvr mice that 
were younger than 4 weeks old and full resistance was not achieved until the mice 
reached 8 to 12 weeks (Bhatt and Jacoby, 1976).  Suppression of the immune system 
which prevented production of antiviral antibodies or T cells during Banzi virus infection 
proved deleterious for both resistant and susceptible mice; suggesting an important role 
for a mature and intact immune system in clearing flavivirus infection (Bhatt and Jacoby, 
1976). Intracerebral inoculation of resistant mice with YFV-17D after injection with anti-
IFN antibodies showed no difference in their Flvr phenotype, illustrating that flavivirus 
resistance is not mediated by interferon (Brinton et al., 1982).  
WNV infection of primary cell cultures prepared from embryofibroblasts derived 
from resistant and susceptible mice produced virus titers that differed by 10 to 100-fold 
(Brinton Darnell and Koprowski, 1974).  Interestingly, analysis of viral RNA produced in 
embryofibroblast cultures from resistant and susceptible mice at very early times after 
WNV infection showed that there were significantly lower amounts of plus-strand RNA 
in the resistant cells than in the susceptible cells; both types of cells had the same amount 
of negative-strand RNA (Brinton, 1981).   
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Virus stress-induced genes 
 Viral stress-inducible genes (VSIG) consist of a common set of genes that are 
inducible by viral infection, dsRNA and interferons (IFN).  Stresses caused by viral 
infection result in a strong and transient induction of these genes (Sarkar and Sen, 2004).  
Although VSIG were initially discovered as IFN-inducible genes, they are capable of 
being induced in an IFN-independent manner (Daly and Reich, 1993; Bandyopadhyay et 
al., 1995; Weaver et al., 1998).  Interestingly, microarray data suggest that the same 
VSIG may be induced via different signaling pathways depending on the inducer (Der et 
al., 1998; Zhu et al., 1998; Chang and Laimins, 2000; Geiss et al., 2001; Johnston et al., 
2001; Mossman et al., 2001; Geiss et al., 2002; Geiss et al., 2003).  The IFN-stimulated 
response element (ISRE) is a cis-acting sequence present in the promoters of all of these 
genes.     
Interferons are divided into type I and type II, and both types have antiviral 
activity (Biron and Sen, 2001; Samuel, 2001; Finter, 1996).  Both types of interferon are 
structurally unrelated and their actions are mediated by different and structurally 
unrelated cell-surface receptors (Sarkar and Sen, 2004).  The type I IFN family includes 
IFN-α, IFN-β, IFN-ω and IFN-τ; while IFN-γ is the only known type II interferon (Sarkar 
and Sen, 2004).  A positive regulatory domain (PRD) and a PRD-like element (PRD-LE) 
are cis-acting elements present in the promoters of IFN-α and IFN-β, respectively; these 
elements are inducible by interferon regulatory factors (IRFs) (Nakaya et al., 2001; and 
references therein).  The IRF-family transcription factors bind to the PRD/PRD-LEs and 
ISREs present in the promoters of IFN and ISGs to induce the transcription of more than 
a 100 genes involved in the antiviral signaling pathways, either IFN-dependent or 
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independent (Nakaya et al., 2001).   The prerequisite for Toll-like receptor 3 (TLR3), but 
not other TLRs, for activation of dsRNA mediated gene induction was demonstrated in 
dsRNA-unresponsive 293 cells that respond to dsRNA in the presence of exogenous 
TLR3 and not other TLRs (Alexpoulou et al., 2001).  The presence of viral dsRNA in 
infected cells elicits phosphorylation of the cytoplasmic domain of TLR3 which leads to 
activation of IRF3, which is constitutively expressed, via adaptor proteins (Jiang et al., 
2004).  Once phosphorylated, IRF3 dimerizes and is then translocated to the nucleus 
where it may form a complex with CBP and p300 forming double-stranded RNA-
activated factor 1 (DRAF1) (Daly and Reich, 1995; Weaver et al., 1998).  DRAF1 can 
bind to ISREs in promoter regions of ISGs to activate transcription of genes such as 
ISG15 and ISG54; DRAF1 also binds to PRD in the IFN-β promoter, inducing 
transcription of IFN-β (Juang et al., 1998; Lin et al., 1998; Sato et al., 1998b; Wathelet et 
al., 1998; Yoneyama, et al., 1998).   IFN produced in the infected cell is secreted and 
binds to receptors on the surface of both infected cells and surrounding uninfected cells.  
IFN binding to the IFN-α/b receptor (IFNAR) causes cross-activation of Jak1 and Tyk2, 
which phosphorylate one another along with STAT1 and STAT2.  The phosphorylated 
STATs form IFN stimulated gene factor 3 (ISGF3), a trimeric complex including STAT1, 
STAT2 and IRF9.  The ISGF3 complex translocates to the nucleus where it binds to 
ISREs in promoter regions to activate transcription of ISGs such as PKR, OAS family 
members and IRF7 (Darnell et al., 1994; Stark et al., 1998; Nakaya et al., 2001).  Once 
phosphorylated due to viral dsRNA, IRF7 moves to the nucleus to further activate IFNα/β 
promoters resulting in massive IFNα/β production that is maintained via a positive feed-
back loop (Nakaya et al., 2001; Marie et al., 1998; Sato et al., 1998a; Au et al., 1998). 
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Gene induction by dsRNAs may be mediated by TLR3 and INF-independent 
pathways.  The protein kinase RNA regulated (PKR) protein contains two dsRNA-
binding motifs (dsRBM) at its N-terminus; when inactive, the dsRBM2 of PKR binds the 
C-terminal kinase domain (Clemens and Elia, 1997).  PKR is in the inactive and closed 
conformation until it interacts with dsRNA which causes the release of the kinase domain 
from dsRBM2 allowing ATP binding resulting in autophosphorylation and activation 
(Nanduri et al., 2000).  Kumar et al. (1997) suggested the presence of a PKR-independent 
mechanism of dsRNA signaling using PKR knock-out (PKR-/-) fibroblasts.  Such a 
mechanism may involve members of the 2′-5′ oligoadenylate synthetase (OAS) family of 
proteins which have been shown to be activated in the presence of dsRNA and ATP, 
leading to degradation of viral and cellular RNAs by RNase L (Hovanessian, 1991; 
Lengyel, 1987; Silverman and Cirino, 1997).   
 
Chromosomal mapping and identification of the Flvr gene 
 Different alleles for natural resistance to Rickettsia tsutsugamushi, which causes 
experimental scrub typhus in mice, were discovered in C3H/He and congenic 
C3H.PRI.Flvr mice at the Ric locus on chromosome 5.  C3H/He mice carry the Rics 
(susceptible) allele, and C3H.PRI.Flvr mice carry the Ricr (resistant) allele (Groves et al., 
1980; Jerrells and Osterman, 1981).  A second locus tightly linked to Ric was 
subsequently identified on chromosome 5 as rd (Lyon and Kirby, 1993).  C3H/He mice 
carry a recessive, defective allele of this gene, which causes retinal degeneration, while 
the C3H.PRI.Flvr mice carry wild-type rd (Bowes et al., 1990; La Vail and Sideman, 
1974).  The differences in the Ric and rd loci in the two mouse strains seemed to 
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segregate with the Flvr gene and the fact that these strains of mice are congenic, 
suggested that the Flvr gene was linked to these two genes.  Three-point backcross 
linkage analyses using 4 chromosome 5 markers, Pgm-1, Eta-1 (Ric synonym), rd, and 
Gus-s (glucuronidase structural gene), showed the gene order was Pgm-1, Eta-, rd, Flvr 
and Gus-s (Sangster et al.,1994; Shellam et al., 1993).  Based on mapping data obtained 
by Urosevic et al. (1997), it was estimated that the Flv gene and the DMit159 
microsatellite were less than 0.15 centiMorgans (cM) apart on mouse chromosome 5 
(Perelygin et al., 2002).  The distance was approximately equivalent to 309 kb and it was 
highly likely (>95 %) that this distance downstream and upstream of the DMit159 
microsatellite would contain the Flv locus (Perelygin et al., 2002).   Twenty-two genes, 
including 10 loci that encoded 2′-5′ oligoadenylate synthetases, were identified 
(Perelygin et al., 2002).  The cDNAs from each of the 22 genes in this region from both 
C3H.PRI.Flvr and C3H/He strains were amplified by RT-PCR, sequenced and compared.  
Of the 22 gene sequences compared, only Oas1b and the Na+/Ca+-exchanger were 
polymorphic; however the Na+/Ca+-exchanger was ruled out as there was no consistent 
correlation between polymorphisms in this gene and the resistant phenotype (Perelygin et 
al., 2002).  The genomic and cDNA sequences of Oas1b revealed that the gene contained 
6 exons and that 4 resistant mouse strains (BRVR, CASA/Rk, Cast/Ei, and C3H.PRI. 
Flvr) encode an identical full-length protein; whereas in 5 susceptible mouse strains 
(129/SvJ, BALB/c, C57BL/6, CBA/J and C3H.PRI. Flvr) an identical truncated protein 
was encoded due to a C820T transition (Perelygin et al., 2002).  The truncation of the 
Oas1b protein was consistently correlated with the susceptible phenotype (Perelygin et 
al., 2002). 
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 The Flv gene was identified as 2′-5′ oligoadenylate synthetase 1b, Oas1b 
(Perelygin et al., 2002).  The resistant allele was designated Flvr, and encodes a full-
length Oas1b protein.  The susceptible allele was designated Flvs, and encodes a C-
terminally truncated protein that also has two amino acid substitutions as compared to the 
Flvr product.  The minor resistance allele was designated Flvmr (Sangster et al., 1993), 
and encodes a full-length Oas1b protein that has 14 amino acid substitutions as compared 
to the Flvr product (Perelygin et al., 2002). 
 
The 2′-5′ oligoadenylate synthetase family 
 Humans, horses, mice and other mammals produce 3 types of 2′-5′ oligoadenylate 
synthetases: small encoded by the Oas1 gene(s), medium encoded by the Oas2 gene and 
large encoded by the Oas3 gene.  Two Oas-like proteins that contain C-terminal 
ubiquitin-like domains are also produced.  The Oas1 unit consists of N- and C-terminal 
domains that are unique to the 2′-5′ oligoadenylate synthetase family and contains a 
central domain with a nucleotidyltransferase fold.  The Oas2 and Oas3 genes consist of 2 
and 3 Oas1 gene units, respectively.  The Oas-like genes consist of the homologous N-
terminus but contain a C-terminal ubiquitin-like domain (Hartmann et al, 1998).  In 
humans, genes in the family are designated OAS, unlike in mice where they are 
designated Oas.  The human OAS genes are located on chromosome 12, while in horses 
they are located on chromosome 8 and in mice they are located on chromosome 5 
(Perelygin et al., 2004).  Recently, Hartmann et al (2003) reported the crystal structure of 
the porcine OAS1 as a monomeric protein that is bilobal in structure.  The first lobe of 
the protein encompasses the large catalytic domain that is connected to the C-terminal 
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domain by a helix-loop-helix linker.  The N-terminus forms a short hook that packs 
against the C-terminal domain to form a tether that maintains a fold which would allow 
the domain-domain interactions that are required for enzymatic activity.  The structure 
formed has a negatively charged cleft containing the active site.  Parallel to the cleft and 
on the back face of the structure is a groove composed of positively charged residues in 
which dsRNA is thought to bind.  Binding of the dsRNA may cause a conformational 
change that widens the cleft of the protein to allow recruitment of the substrate ATP 
which then leads to the synthesis of 2′-5′ oligoadenylates (Hartmann et al., 2003).  The 
human OAS1 and the mouse Oas1a and Oas1g are functionally active 2′-5′ 
oligoadenylate synthetases.  The human hOASL and its murine ortholog mOasl1 are not 
functionally active, while the mouse mOasl2 was shown to be a functionally active 
synthetase (Eskildsen et al., 2003). 
 
Murine Oligoadenylate Synthetases 
 
Mice produce 3 types of 2′-5′ oligoadenylate synthetases, small (40-47 kDa) 
encoded by the Oas1a-Oas1h genes, medium (85-86 kDa) encoded by the Oas2 gene, and 
large (126 kDa) encoded by the Oas3 gene.  Mice also produce two Oas-like proteins.  
The small 2′-5′ oligoadenylate synthetases contain 3 functional motifs; an N-terminal 
LXXXP motif required for 2′-5′ oligoadenylate synthetase activity, a P-loop motif that 
has been suggested to be required for ATP-binding, and a DAD Mg2+ binding motif also 
required for synthetase function.  Active 2′-5′ oligoadenylate synthetases bind double-
stranded RNA and some double-stranded regions within folded single-stranded RNA 
(Maitra et al., 1998; Desai et al., 1995; Sharp et al., 1999) and produce 2′-5′ 
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oligoadenylate by polymerizing ATP through 2′-5′ linkages.  One cellular defense 
mechanism involves the activation of a latent endoribonuclease called RNase L.  2′-5′ 
oligoadenylates produced by activated 2-5A synthetases activate RNase L.  Once 
activated, RNase L dimerizes and degrades viral and cellular single-stranded RNAs after 
UA and UU dinucleotides (Wreschner, et al. 1981).  Although the functions of 2′-5′ 
oligoadenylates and RNase L are virus non-specific (Hovanessian and Wood, 1980; 
Clemens and Williams, 1978), the antiviral effect of the Oas1b gene product is specific to 
members of the flavivirus genus (Perelygin et al., 2002). 
 
Goals of the project 
 
 Resistance to flavivirus-induced disease was demonstrated in mice and showed 
monogenic autosomal dominant inheritance.  The flavivirus resistance gene, Flv, in mice 
has been identified as 2′-5′ oligoadenylate synthetase 1b (Oas1b).  Susceptible mice 
produce a protein that is truncated (Oas1btr) at the C-terminus due to a premature stop 
codon encoded by a C820T transition.  The truncation comprises 30 % of the C-terminus 
of the protein.  Mice produce 8 Oas1 proteins, Oas1a-Oas1h.  Oas1a and Oas1g were 
previously reported to be functional 2-5A synthetases.  Poly (I:C) binding was also 
reported for Oas1a, Oas1c, Oas1d, Oas1e, Oas1f, Oas1g, Oas1h and Oas1btr proteins 
(Kakuta et al., 2002).  The full-length Oas1b had not yet been tested for either 2-5A 
synthetase activity or RNA binding activity.  The first goal of this project was to express 
Oas1a, Oas1b and Oas1btr in bacteria and to purify the expressed proteins.  The second 
goal was to test the expressed Oas1 proteins for 2-5A synthetase activity to determine 
whether Oas1b had synthetase activity.  The final goal of the project was to test the 
ability of the expressed Oas1 proteins to bind to synthetic and viral RNAs.   
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MATERIALS AND METHODS 
Cloning of Oas1 proteins into pMAL-c2G vectors:  pHeTopoXL1a, previously 
constructed by Dr. Perelygin, and primers containing the SnaBI and BamHI restriction 
sites were used to clone the Oas1a gene into pCR-XL-TOPO with the TOPO-TA cloning 
kit (Invitrogen).  The construct was named pTopoXL1a#10.  pTopoXL1a#10 and pMAL-
c2G vector DNAs were digested with SnaBI and BamHI.  The digestion was done 
sequentially; briefly, pTopoXL1a#10 and pMAL-c2G DNAs were each digested with 
BamHI and then QIAGEN’s PCR purification protocol was used to purify the DNA.  The 
cut pTopoXL1a#10 and pMAL-c2G DNAs were digested with SnaBI.  The reactions 
were then electrophoresed on a 1% TBE agarose gel.  The vector and the 1101 bp Oas1a 
gene insert were isolated using the QIAGEN Gel Extraction protocol.   
pScreen1b#18, previously constructed by Dr. Scherbik, and primers containing 
the SnaBI and BamHI restriction sites were used to clone the full-length Oas1b gene into 
pCR-XL-TOPO by using the TOPO-TA cloning kit (Invitrogen).  The construct was 
named pTopoXL1b#1.  pTopoXL1b#1 and pMAL-c2G vector DNAs were digested with 
SnaBI and BamHI.  The digestion was done sequentially; briefly, pTopoXL1b#1 and 
pMAL-c2G DNAs were each digested with BamHI and then QIAGEN’s PCR 
purification protocol was used to purify the DNA.  The cut pTopoXL1b#1 and pMAL-
c2G DNA were digested with SnaBI.  The reactions were then electrophoresed on a 1% 
TBE agarose gel.  The vector and the 1128 bp Oas1b gene insert were isolated using the 
QIAGEN Gel Extraction protocol.   
Using the TOPO-TA cloning kit (Invitrogen), pTopoXL1btr#2, which contained 
the Oas1btr gene, was constructed by using pTopoXL1b#1 as a template along with 
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primers containing the SnaBI and BamHI.  The BamHI-containing primer also encoded a 
C-T transition in the Arg codon at position 757 resulting in a stop codon.  
pTopoXL1btr#2 and pMAL-c2G vector DNAs were digested with SnaBI and BamHI.  
The digestion was done sequentially; briefly, pTopoXL1btr#2 and pMAL-c2G DNAs 
were each digested with BamHI and then QIAGEN’s PCR purification protocol was used 
to purify the DNA.  The cut pTopoXL1btr#2 and pMAL-c2G DNAs were digested with 
SnaBI.  The reactions were then electrophoresed on a 1% TBE agarose gel.  The vector 
and the 756 bp Oas1btr gene insert were isolated using the QIAGEN Gel Extraction 
protocol.   
The vectors and inserts were ligated using T4 DNA ligase according to a modified 
protocol.  Briefly, the vector and insert DNAs were heated to 45°C for 5 minutes and 
cooled on ice prior to addition of the T4 DNA ligase.  The ligation reaction was 
incubated at 16°C overnight.  The reaction was then heated to 65°C to inactivate the 
ligase and cooled on ice.  The ligation reaction was then transformed into TOP10 One 
Shot Chemically competent cells and plated on LB + AMP plates.  The transformation 
was modified to include two minutes of heat-shocking the competent cells and a longer 
incubation than usual.  PCR screening was performed on the colonies using primers 
specific to the insert.  The colonies were cultured and plasmid miniprep kits were used to 
isolate plasmids from the cells.  After isolating the plasmids, a sequencing reaction was 
run on each plasmid using malE forward and M13/pUC reverse primers to check the 
sequence. 
 Expression of MBP-Oas1 Proteins:  pMAL-O1aQCR was used to transform 
BL21 (non-D3E) cells for the expression of recombinant Oas1a (MBP-Oas1a) protein.  
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Five mls of culture were grown overnight at 37°C.  The 5 mls of overnight culture was 
added to 250 mls of Rich Media with 0.05% glucose and 75 mg/ml of carbenicillin 
(CRB) and grown at 37°C until the culture reached an OD600 of ~0.75.  Two 1 ml 
samples were collected and centrifuged at 14,000 x g for 2 minutes.  The supernatant was 
removed and the pellet was resuspended in 100 µl of 2x SDS buffer with 5 % β-
mercaptoethanol (β-ME); this was the uninduced sample.  The rest of the culture was 
induced with 1 mM IPTG overnight at 16°C.  Two 1 ml samples were collected from the 
overnight-induced culture and centrifuged at 14,000 x g for 2 minutes.  The supernatant 
was removed and the pellet was resuspended in 100 µl of 2x SDS buffer with β-
mercaptoethanol; this was the induced sample.  The rest of the culture was pelleted by 
centrifugation at 5,000 x g for 15 minutes.  The supernatant was removed and 
resuspended in 5 ml of column buffer (20 mM tris-HCl, 200 mM NaCl, 1 mM EDTA and 
10 mM β-ME) and frozen at -20°C until use.   
pMAL-O1b was used to transform BL21 (nom-DE3) cells for expression of 
recombinant Oas1b (MBP-Oas1b) protein.  Five mls of culture were grown overnight at 
37°C.  The 5 mls of overnight culture was added to either 500 mls of TB Autoinduction 
media (Novagen) with 0.05% glucose and 75 mg/ml of carbenicillin (CRB), or 500 mls 
of LB media with 0.05% glucose and 75 mg/ml of carbenicillin (CRB); cultures were 
grown at 37°C until the culture reached an OD600 of ~0.6.  Two 1 ml samples were 
collected and centrifuged at 14,000 x g for 2 minutes.  The supernatant was removed and 
the pellet was resuspended in 100 µl of 2x SDS buffer with 5 % β-ME; this was the 
uninduced sample.  The rest of the culture was either induced with 0.5 mM IPTG in LB 
or allowed to grow for auto-induction without IPTG overnight at 16°C.  Two 1 ml 
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samples were collected from the overnight-induced culture and centrifuged at 14,000 x g 
for 2 minutes.  The supernatant was removed and the pellet was resuspended in 100 µl of 
2x SDS buffer with 5 % β-ME; this was the induced sample.  The rest of the culture was 
pelleted by centrifugation at 5,000 x g for 15 minutes.  The supernatant was removed and 
resuspended in 3 ml of column buffer and frozen at -20°C until use. 
pMAL-O1btr was used for the expression of recombinant Oas1btr (MBP-Oas1btr) 
protein in BL21 (non-D3E) bacterial cells.  Five mls of culture were grown overnight at 
37°C.  The 5 mls of overnight culture were added to 250 mls of Rich media with 0.05% 
glucose and 75 mg/ml of carbenicillin (CRB) and grown at 37°C until the culture reached 
an OD600 of ~0.5.  Two 1 ml samples were collected and centrifuged at 14,000 x g for 2 
minutes.  The supernatant was removed and the pellet was resuspended in 100 µl of 2x 
SDS buffer with 5 % β-ME; this was the uninduced sample.  The rest of the culture was 
induced with 0.5 mM IPTG overnight at 16°C.  Two 1 ml samples were collected from 
the overnight-induced culture and centrifuged at 14,000 x g for 2 minutes.  The 
supernatant was removed and the pellet was resuspended in 100 µl of 2x SDS buffer with 
5 % β-ME; this was the induced sample.  The rest of the culture was pelleted by 
centrifugation at 5,000 x g for 15 minutes.  The supernatant was removed and 
resuspended in 5 mls of column buffer and frozen at -20°C until further use. 
 Purification of MBP-Oas1 protein:  The Oas1 recombinant proteins were 
successfully purified by column purification using amylose resin.  Cultures for the 
expression of MBP-Oas1a, MBP-Oas1b and MBP-Oas1btr were prepared as described 
above.  The cultures were pelleted and the cells were resuspended in column buffer and 
lysed using a French press. 
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 The soluble fraction (crude) and insoluble fraction were separated by 
centrifugation at 10,000 x g for 20 minutes.  The crude sample was diluted 1:5 in column 
buffer and loaded onto a 2.5 cm x 10 cm column that contained 2 ml of equilibrated 
amylose resin.  The sample was allowed to flow through the column, collected and 
reloaded onto the column three times to ensure that the protein efficiently bound to the 
resin.  The resin was washed with 100 ml of column buffer, and the MBP-fusion protein 
was then eluted from the column with 10 mM maltose in column buffer.   
 Alternatively, the Oas1 proteins were purified using ion exchange 
chromatography by loading the crude sample onto an anion exchange column (HiTrap Q 
HP).  The proteins in the samples were separated by a salt gradient.  Buffer A is 20 mM 
Tris-HCl, pH 7.6 and buffer B is 20 mM Tris-HCl, pH 7.6 and 1M NaCl.  The MBP-
Oas1a protein was eluted between concentrations of 550 mM and 800 mM NaCl.  The 
MBP-Oas1b protein was eluted between concentrations of 600 mM and 750 mM NaCl.  
The MBP-Oas1btr protein was eluted between concentrations of 500 mM and 750 mM 
NaCl.  The protein concentrations obtained using the FPLC were very low and had to be 
concentrated 100-fold to be visualized after SDS-PAGE. 
Cleavage of the MBP fusion:  In a reaction tube, 5.5 µl of Genenase I (1 µg/µl) 
was added to 520 µl of MBP-Oas1a (600 ng/µl) and incubated at room temperature.  Five 
µl samples were taken from the digestion reaction at 2, 4, 24 and 28 hours.  In a separate 
tube, 5 µl of fusion protein were incubated for 28 hours; this was the mock digestion 
sample.  Five µl of fusion protein were mixed with 2X SDS gel-loading buffer with 5 % 
β-ME at the end of the digestion period; this was the uncut fusion sample.  Each sample 
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was mixed with 2X SDS gel-loading buffer containing 5 % β-ME, boiled for 5 minutes 
and stored at 4°C until analyzed.  Samples were electrophoresed on a 10 % SDS-PAGE. 
Separation of Oas1a from MBP by hydroxyapatite chromatography:  One g 
of hydroxyapatite was reconstituted in buffer C [20 mM sodium phosphate, 200 mM 
NaCl (pH 7.2)].  The resin was allowed to settle and excess buffer was carefully decanted 
as to not disturb the resin. Fresh buffer was added and this process was repeated twice.  
The hydroxyapatite was poured into a disposable 1 x 10 cm column (BD Clontech).  Five 
hundred µl of the fusion protein cleavage mixture was loaded onto the column.  The 
column was washed with 80 ml of buffer C to wash away the maltose.  Twenty ml of 0.5 
M sodium phosphate (pH 7.2) were used to elute the Oas1a protein, the MBP fusion and 
the protease.  The column was reloaded twice more to ensure complete elution of protein.  
The eluate was then loaded onto an amylose column.  The flow-through was collected 
and reloaded twice more to increase the efficiency of binding of the MBP fusion 
fragment to the amylose resin.  The flow-through was concentrated to 450 µl and stored 
at -80°C until use. 
Western blotting:  MBP-Oas1 proteins were separated under denaturing and 
reducing conditions on a 10 % SDS-PAGE.  The proteins were transferred to a PVDF 
membrane and the membrane was blocked overnight at 4°C with 5 % bovine serum 
albumin (BSA) in Tris-buffered saline [10 mM Tris-HCl (pH 8.0), 150 mM NaCl] (TBS).   
A horseradish peroxidase (HRP) conjugated anti-MBP (monoclonal murine anti-
MBP, New England Biolabs) antibody was used to detect the MBP-Oas1 proteins.  The 
membrane was incubated with antibody diluted 1:35,000 in a 5 % BSA-TBS solution at 
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room temperature for 1.5 hrs.  The membrane was washed with 15 ml of a 0.05 % 
Tween-20-TBS solution (TBS-T) for 15 minutes 6-8 times.   
For detection of the Oas1a protein after cleavage of MBP, an anti-OAS1 antibody 
(chicken anti-human-OAS1 IgY, Genway Biotech) was used.  The membrane was 
incubated with anti-OAS1 antibody diluted 1:2,000 in a 5 % BSA-TBS solution at room 
temperature for 1.5 hrs.  The membrane was washed with 15 ml of TBS-T for 15 minutes 
6-8 times.  The membrane was then incubated with a HRP-conjugated goat anti-IgY Fc 
(Genway Biotech) antibody diluted 1:3,000 in a 5 % BSA-TBS-T solution at room 
temperature for 1.5 hrs.  The membrane was washed with 15 ml of TBS-T for 15 minutes 
6-8 times.   
After the last wash, West Pico Enhanced Chemiluminescence reagent (Pierce) 
was added to the membrane for 5 minutes at room temperature.  The membrane was 
exposed with autoradiography film. 
 2′-5′ Oas activity assay:  MBP-Oas1 fusion proteins were assayed for 2′-5′ Oas 
activity.  Each of the MBP-Oas1 fusion proteins was added to reaction mixtures at 
increasing concentrations.  The 50 µl reaction mixture contained 2′-5′ OAS activity assay 
buffer (20 mM HEPES-KOH pH 7.5, 50 mM KCl, 25 mM Mg(OAC)2, 10 mM creatine 
phosphate, 1U/µl creatine kinase, 5 mM ATP, and 7 mM β-ME), 50 µg/ml poly (I:C), 10 
µCi 32p-ATP.  The reaction was incubated at 30°C for 18 hrs.  The synthesis reaction was 
stopped by addition of 50 µl of 2x gel loading buffer (95% formamide, 18 mM EDTA, 
0.025% SDS, xylene cyanol, and bromophenol blue).  Four µl of each reaction were 
loaded onto a 20% polyacrylamide gel and electrophoresed at 1800 V for 3.5 hrs.  The 
gel was exposed to an autoradiography film for 1-24 hrs.  
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Synthesis of RNA probes:  Three probes were constructed to test the ability of 
the MBP-Oas1 fusion proteins to bind dsRNAs.  The first probe, designated 3′ (+) UA 
Probe #1, encompassed nucleotides 10387-10448 of the WNV Eg101 genome.  The 
second probe, designated 3′ (+) Control Probe #2, encompassed nucleotides 10308-10364 
of the WNV Eg101 genome.  The third probe, designated 3′ (+) SL Probe #3, 
encompassed bases 10931-11029 of the WNV Eg101 genome.  The probes were 
synthesized using the in vitro T7 RNA polymerase MAXIscript protocol (Ambion) in the 
presence of radiolabeled UTP (32p-UTP).  The RNA transcripts were gel-purified and 
partially purified by precipitation.   
Gel electrophoresis mobility shift assay:  The binding activity of each of the 
MBP-Oas1 fusion proteins was tested by gel mobility shift assay using various RNA 
probes from the 3′ end of the WNV genome.  Proteins were added into binding reactions 
containing 1X Gel Shift Buffer (3% Ficoll-400, 20 mM sodium phosphate pH 7.2, 60 
mM KCl, 1 mM MgCl2, and 0.5 mM EDTA), 0.2 ul of RNasin, 35 ng of yeast tRNA as 
non-specific competitor, 10 mM (DTT) dithiothreitol, and radiolabeled RNA.  Reactions 
were incubated at room temperature for 20 minutes and then stopped by the addition of 
gel loading buffer (0.025% bromophenol blue, 0.025% xylene cyanol, 4% sucrose, and 
1X Tris borate-EDTA).  The reactions were electrophoresed on non-denaturing 5% 
polyacrylamide gels (39:1 acrylamide:bis-acrylamide, and 1X Tris borate-EDTA) at 120 







Cloning and expression of MBP-Oas1 proteins in bacteria 
Initial attempts to express the full-length Oas1b protein using a pET16b 
expression vector (Novagen) yielded proteins that were insoluble and were mainly in 
inclusion bodies.  The concentrations of expressed proteins were inadequate for 
purification.  The expressed protein contained a 10X histidine tag at the N-terminus.  The 
use of different strains of bacteria and different growth and induction conditions failed to 
alleviate the problems encountered with expression using the pET system (data not 
shown).  As a result, the pMAL Protein Fusion and Purification System was subsequently 
used to express soluble Oas1b proteins that were fused to maltose binding protein (MBP).  
Recombinant proteins expressed using the pMALc2G vector contained the MBP fusion at 
the N-terminus and were soluble.   
The cDNAs of the full-length and truncated Oas1b proteins as well as of the 
Oas1a protein were each cloned into the pMAL-c2G expression vector.  The expressed 
fusion protein consisted of a 42.5 KDa maltose-binding protein linked to the Oas1 protein 
by 10 Asp residues.  Each of the constructs was used to express recombinant Oas protein 
in BL21 bacterial cells.  Cultures were grown at 37°C until an OD600 of approximately 
0.6 was reached.  The cultures were induced with IPTG overnight at 16°C.  Samples were 
collected and resuspended in 100 µl of 2X SDS gel loading buffer.  Expression of the 
fusion proteins was analyzed by electrophoresis of 15 µl from each sample on a 10 % 
SDS polyacrylamide gel (Fig. 1).   
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Figure 1:  Expression of Oas1a, Oas1b and Oas1btr proteins in bacteria. Total proteins 
were separated by 10% SDS-PAGE. (A)  Expression of MBP-Oas1a in BL21 (non-DE3) 
cells.  Lane 1:  Uninduced cells.  Lane 2:  Cells induced with 1mM IPTG overnight at 
16°C. (B) Expression of MBP-Oas1btr in BL21 (non-DE3) cells.  Lane 1:  Uninduced 
cells.  Lane 2:  Cells induced with 1mM IPTG overnight at 16°C.  (C) Expression of 
MBP-Oas1b in BL21 (non-DE3) cells.  Lane 1:  Uninduced cells.  Lane 2:  Cells 
induced with 0.5mM IPTG overnight at 16°C.  M:  Molecular weight markers, Precision 
Plus protein standards (Bio-Rad).  
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 Interestingly, the expression of MBP-Oas1a was more efficient than that of MBP-
Oas1b and MBP-Oas1btr; also, the observed expression level of MBP-Oas1btr was 
noticeably higher than that of MBP-Oas1b. 
 
Purification of MBP-Oas1 fusion proteins 
 MBP-Oas1 fusion proteins were purified from cultures of BL21 bacterial cells.  
Each of the expressed fusion proteins was soluble (Fig. 2A lane 3, Fig. 2B lane 3, Fig. 
2C lane 1).  Cell pellets from induced cultures were resuspended in column buffer 
containing protease inhibitor cocktail to minimize protein degradation and all purification 
steps were carried out at 4°C.  The cells were lysed by using a French press and the 
suspension was clarified by centrifugation.  MBP-Oas1 fusion proteins were purified 
using amylose resin as described in Methods.  Protein eluted from the resin was 
concentrated by using Centricon YM-30 concentrators (Millipore) and separated by 10 % 
SDS-PAGE.   
MBP-Oas1a, MBP-Oas1b, and MBP-Oas1btr were successfully purified by 
amylose resin column purification (Fig. 2A lanes 7 and 8, Fig. 2B lanes 6-8; Fig. 2C 
lane 1).  MBP-Oas1btr was initially purified by chromatography on an anion exchange 
column (HiTrap Q HP) as described in Methods (Fig. 2D).  Although extremely pure, the 
amount of MBP-Oas1btr recovered using this method was not sufficient for 
experimentation.  MBP-Oas1btr was subsequently purified using the amylose resin 
column method to recover larger amounts of the protein.  The presence of the MBP-Oas1 
proteins was confirmed by Western blotting (Fig. 3); the proteins were detected using 
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anti-MBP-HRP antibody.  The results of these experiments confirmed the expression and 
purification of MBP-Oas1 proteins using the pMAL system. 
   













1                   M                          
MBP-Oas1btr












M           1            2            3            4          5            6           7           8
MBP-Oas1a
 
Figure 2:  Purification of Oas1 proteins.  (A)  Purification of MBP-Oas1a from BL21 
(non-DE3) cells by amylose resin.  Lane 1:  Uninduced cells.  Lane 2:  Cells induced 
with 1mM IPTG for 18 hrs at 16°C. Lane 3:  Cell supernatant obtained after French press 
lysis and centrifugation. Lane 4:  Flow through #1. Lane 5:  Wash #1. Lane 6:  Flow 
through #2.  Lanes 7 & 8:  Eluate.  (B) Purification of MBP-Oas1b from BL21 (non-
DE3) cells by amylose resin.  Lane 1:  Uninduced cells.  Lane 2:  Cells induced with 
1mM IPTG for 18 hrs at 16°C. Lane 3:  Cell supernatant after French press lysis and 
centrifugation. Lane 4:  Flow through. Lane 5:  Wash. Lane 6-8: Eluate.  (C)  
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Purification of MBP-Oas1btr with amylose resin.  Lane 1: Eluate.  Proteins were 
fractionated by 10% SDS-PAGE.  (D)  Purification of MBP-Oas1btr by Ion Exchange 












Figure 3:  Representative western of MBP-Oas1 proteins purified by amylose resin.  
Lane 1:  MBP-Oas1b.  Lane 2:  MBP-Oas1a.  Lane 3: MBP-Oas1btr.  Proteins were 
separated by 10 % SDS-PAGE.  M:  Molecular weight markers, Precision Plus protein 
standards (Bio-Rad). 
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Cleavage of MBP from the MBP-Oas1a fusion protein 
 Since the MBP-Oas1a fusion protein was the most abundant of the purified 
proteins, it was used first to see if the MBP fusion could be removed by Genenase I 
digestion and if Oas1a could successfully be recovered.  Digestion with Genenase I was 
fairly efficient, as there was only a small amount of the fusion protein which could be 
visualized by gel staining compared to the uncut fusion after 28 hours of digestion (Fig 4, 
lane 6). 











Figure 4:  Cleavage of Oas1a from MBP by Genenase I.  Approximately 315 µg of 
purified MBP-Oas1a were digested with Genenase I for 28 hours at room temperature.  
Lane 1:  2 µl of a mock digestion containing protein only was incubated for 28 hrs  Lane 
2: 10 µl of uncut fusion protein  Lane 3: 10 µl of protein digested for 2 hrs  Lane 4: 10 
µl of protein digested for 4 hrs  Lane 5: 10 µl of protein digested for 24 hrs  Lane 6: 10 
µl of protein digested for 28 hrs   M:  Molecular weight markers, Precision Plus protein 
standards (Bio-Rad).  Proteins were separated by 10% SDS-PAGE.   
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After digestion with Genenase I for 28 hrs, undigested MBP fusion protein was 
separated from released Oas1a using hydroxyapatite and amylose resin chromatography 
(Fig. 5A).  Oas1a, the MBP fusion, and Genenase I were eluted from the column; co-
elution of Genenase I did not cause a problem since it was present, at most, as 1 % of the 
eluted proteins.  The eluted proteins were then loaded onto an amylose column to bind 
both free MBP and uncut fusion proteins.  However, a limitation of this technique is that 
any MBP that has been denatured, damaged, or misfolded will not bind to the amylose 
column and, so will not be removed from the flow-through.  Indeed, MBP fusion, which 
is 42.7 kDa, was detected comigrating with the purified Oas1a, which is 42.5 kDa; this 
was demonstrated by comparing western blots done with anti-MBP-HRP antibody and 
anti-OAS1 antibody.  Although the SDS-PAGE showed a single band at ~43 kDa, this 
same band was detected by both antibodies (Fig. 5B, lanes 3-4), indicating that some 
MBP was still present in the purified Oas1a sample.  Commercially available MBP2* 
(42.5 kDa) was not detected with the anti-OAS1 antibody. 
The results of these experiments show that although cleavage of MBP from Oas1a 
was successful, it was not possible to separate the two cleavage products efficiently.  
Although it may have been possible to separate these two proteins by different methods, 
such as ion exchange chromatography, other methods were not employed due to the poor 
recovery of the proteins.  In order to investigate whether the removal of the MBP fusion 
was necessary for synthetase activity, the 2′-5′ OAS activity of MBP-Oas1a was next 
tested. 
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Figure 5:  Analysis of cleavage products by western blotting. (A) Proteins from a 28 hrs 
Genenase I cleavage reaction were separated by 10% SDS-PAGE. Lane 1:  MBP-Oas1a.  
Lane 2:  Control MBP2*.  Lane 3: MBP-Oas1a digested for 24 hrs.  Lane 4: Oas1a 
separated by hydroxyapatite chromatography. (B)  Representative western blots Lane 1:  
Uncut MBP-Oas1a detected with anti-MBP-HRP antibody.  Lane 2:  Control MBP2* 
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detected with anti-MBP-HRP antibody.  Lane 3:  Hydroxyapatite-purified cleavage 
products detected with anti-OAS1 antibody.  Lane 4: Hydroxyapatite-purified cleavage 
products detected with anti-MBP-HRP antibodies.  M:  Molecular weight marker, 
Precision Plus protein standards (Bio-Rad).  Hydroxyapatite-purified cleavage products 
were separated by 10% SDS-PAGE. 
 
MBP-Oas1a is a functional synthetase 
Based on the crystal structure of the porcine OAS1 protein, Hartmann et al. 
(2003) predicted that the N-terminal hook of the porcine OAS1 would fold into the 
protein and pack against the C-terminal domain to form a tether that would maintain a 
fold which would allow the domain-domain interactions required for enzymatic activity.  
This structure predicts that the presence of a fusion at the N-terminus of this protein 
would prevent proper folding and abolish synthetase activity.  However, human OAS1 
shares greater homology with the porcine OAS1 than do the murine Oas1a or Oas1b 
proteins.  Therefore, it was necessary to test whether an N-terminal fusion would 
interfere with the enzymatic activity of murine Oas1a.  Reaction mixtures containing 2′-5′ 
OAS buffer and different amounts of protein were incubated for 18 hrs at 30°C.  The 
products were separated by 20 % PAGE and the bands visualized by autoradiography.   
 Previously Kakuta et al. (2002) used bacterially expressed, unpurified Oas1a that 
contained a 10X histidine tag at its N-terminus to demonstrate that recombinant Oas1a 
was a functionally active synthetase.  MBP-Oas1a showed 2′-5′ OAS activity at 
concentrations from 0.5 µg to 16 µg (Fig. 6, lanes 4-7).  Purified Oas1a protein, which 
had the MBP fusion removed, also showed 2′-5′ OAS activity (Fig. 6, lane 3).  
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Comparison of the 2-5A synthesized by 0.75 µg of Oas1a and MBP-Oas1a showed that 
the activities of the two proteins were similar.  The lowest tested protein concentration 
showing detectable synthetase activity was 0.75 µg for Oas1a and 0.5 µg MBP-Oas1a.  
At concentrations lower than 0.5 µg no activity was detected (data not shown).  MBP2*, 
a commercially available maltose-binding protein, has the same amino acid sequence as 
the MBP fusion except that it does not contain the 10 amino acid polylinker present in the 
fusion protein.  As a control, MBP2* was also tested for 2′-5′ OAS activity (Fig. 6, lane 
2).  MBP2* did not exhibit any 2′-5′ OAS activity indicating that the 2′-5′ OAS activity 
shown by the fusion protein could not have been contributed by the MBP fusion. As 
stated above, since free MBP was not completely removed from Oas1a after cleavage 
with Genenase I, the Oas1a protein concentration measured was not accurate. 
 These results showed that bacterially expressed MBP-Oas1a and its cleaved 
product, Oas1a, were enzymatically functional proteins. Such an observation suggests 
that the proper folding of MBP-Oas1a into a catalytically active form was not hindered 
by the presence of the MBP fusion.  These results also indirectly confirmed that the 
MBP-Oas1a protein was able to bind poly (I:C), since binding of poly (I:C) is required to 
activate a 2′-5′ oligoadenylate synthetase.   
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Figure 6:  Analysis of the 2-5A synthetase activity of MBP-Oas1a. Different amounts of 
MBP-Oas1a protein were incubated with α32p-ATP and poly (I:C) for 18 hrs at 30°C.  
Four µl of each reaction were separated on a 20% polyacrylamide-urea denaturing gel.  
Lane 1:  No protein.  Lane 2:  16 µg of MBP2*.  Lane 3:  0.75 µg of Oas1a.  Lane 4:  
0.5 µg of MBP-Oas1a.  Lane 5:  0.75 µg of MBP-Oas1a.  Lane 6:  1 µg of MBP-Oas1a.  
Lane 7:  16 µg of MBP-Oas1a. 
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MBP-Oas1b is a non-functional oligoadenylate synthetase 
A truncated form of Oas1b (Oas1btr) was previously cloned from the flavivirus-
susceptible C57BL/6J mouse strain, and expressed as an N-terminally 10X histidine-
tagged fusion protein in E. coli.  When this Oas1btr was tested for 2-5A synthetase 
activity, it was found to be enzymatically non-functional (Kakuta et al., 2002).  In the 
present study, both Oas1a and MBP-Oas1a were shown to have 2′-5′ OAS activity (Fig. 
6, lane 3 and lanes 4-7, respectively); MBP-Oas1a was used as a positive control while 
MBP-Oas1btr was used as a negative control.  The full-length Oas1b, MBP-Oas1b, was 
tested for synthetase activity.  Reaction mixtures containing 2-5A synthetase buffer and 
different amounts of protein were incubated for 18 hrs at 30°C.  The products were 
separated by 20 % PAGE and the bands visualized by autoradiography.  Neither MBP-
Oas1b nor MBP-Oas1btr showed any 2′-5′ OAS activity (Fig. 7, lane 3 and lane 2, 
respectively) using 2.6 µg of each protein.  This concentration was more than 4 times 
higher than the lowest active concentration of MBP-Oas1a tested.  These results 
demonstrate that MBP-Oas1b is not a functional 2-5A synthetase.  However, preliminary 
results suggest that MBP-Oas1b is able to bind ATP and modify it somehow. 
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Figure 7:  Analysis of the 2′-5′ OAS activity of MBP-Oas1b protein.  Different amounts 
of protein were incubated with α32p-ATP and poly (I:C).  Two µl of each reaction were 
separated on a 20% polyacrylamide-urea denaturing gel.  Lane 1:  No protein.  Lane 2:  
2.3 µg of MBP-Oas1btr.  Lane 3:  2.6 µg of MBP-Oas1b.  Lane 4:  1 µg of MBP-Oas1a.  
Lane 5:  0.75 µg of MBP-Oas1a.  Lane 6:  0.5 µg of MBP-Oas1a. 
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WNV (+) 3′ RNA binding activity of MBP-Oas1 proteins 
 Activation of 2′-5′ Oas proteins requires the binding of dsRNA or some ds-
regions within ssRNA.  Extensive base pairing is found in several small viral RNA 
genomes (Maitra et al., 1998; Desai et al., 1995; Sharp et al., 1999).  To further 
investigate the RNA binding activity of MBP-Oas1a, MBP-Oas1b, and MBP-Oas1btr, 3 
radiolabeled RNA probes were constructed from different regions of the 3′ end of WNV 
Eg101.  The probes were folded using the mfold server (Zucher, 2003; Mathews et al., 
1999) (Fig. 8A) to check that they folded into the optimal secondary structure predicted 
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Figure 8:  Secondary structure predictions of three WNV RNA probes using only the 
stem-loop sequence (A) mfold Server (Zucher, 2003; Mathews et al., 1999) or (B) as part 
of a whole genome fold (Sgro and Palmenberg, unpublished data). 
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The first probe tested was (+) 3′ UA Probe #1, which encompassed nucleotides 
10387-10448 of the WNV Eg101 genome.  The sequence of this probe spans the last 10 
nucleotides of the NS5 viral gene including the stop codon and the first 57 nucleotides of 
the 3′ UTR.  This probe has a sequence that is AU-rich.  To determine the optimal 
concentration of non-specific competitor that should be included in RNA binding 
reactions, MBP2* in large excess (16 µg) was incubated with (+) 3′ UA Probe #1 in the 
presence of increasing concentrations of yeast tRNA (Fig. 9).  The data indicated that 
~100 ng of tRNA would be sufficient to compete out most of the non-specific binding to 
MBP2* when it is present in large excess (4 to 16 times) compared to the concentrations 
used in subsequent gel mobility shift assays.  The majority of the non-specific binding 
activity was competed by the addition of as little as 10 ng of yeast tRNA. 
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Figure 9:  Gel mobility shift assay to determine the optimal non-specific competitor 
concentration.  MBP2* (16 µg) was incubated with (+) 3′ UA Probe #1 (2000 cpm) and 
increasing concentrations of tRNA.  The amounts of competitor were:  Lane 1:  0.  Lane 
2: 5 ng.  Lane 3:  10 ng.  Lane 4:  25 ng.  Lane 5: 50 ng.  Lane 6: 75 ng.  Lane 7: 100 
ng.  FP:  Free probe.  Binding reactions were separated on a 6 % polyacrylamide non-
denaturing gel.  Bands on the dried gel were detected by A.  PhosphorImaging.  B.  
Autoradiography. 
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Based on these results, 30-50 ng of yeast tRNA was used to compete out non-
specific binding to the MBP-portion of the fusion proteins and free MBP in the samples.  
A MBP2* reaction that contained 2 times the highest amount of fusion protein used in the 
assay was included in each subsequent gel shift experiment.  Different concentrations of 
MBP-Oas1a (200 to 800 ng) and MBP-Oas1b (200 to 600 ng) were next used to test their 
ability to bind to (+) 3′ UA Probe #1 (Fig. 10).   
0.2      0.4       0.6      0.8       0.2       0.4    0.6 ug
MBP-Oas1bMBP-Oas1a
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Figure 10:  Gel shift mobility assay with (+) 3′ UA Probe #1.  Various concentrations of 
MBP-Oas1a (lanes 2-5) or MBP-Oas1b (lanes 6-8) were incubated with (+) 3′ UA Probe 
#1 (2000 cpm).  Lane 1:  Free probe.  Lane 2: 200 ng of MBP-Oas1a.  Lane 3:  400 ng 
of MBP-Oas1a.  Lane 4:  600 ng of MBP-Oas1a.  Lane 5: 800 ng of MBP-Oas1a.  Lane 
6: 200 ng of MBP-Oas1b.  Lane 7: 400 ng of MBP-Oas1b.  Lane 8:  600 ng of MBP-
Oas1b.  Binding reactions were separated on a 6 % polyacrylamide non-denaturing gel.  
Bands on the dried gel were detected by A.  PhosphorImaging.  B.  Autoradiography. 
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These results indicated that both MBP-Oas1a and MBP-Oas1b can bind to (+) 3′ 
UA Probe #1; however, the MBP-Oas1b appeared to have a higher binding activity to 
this probe than MBP-Oas1a.  To determine the lowest concentration at which these 
proteins bind this RNA probe, MBP-Oas1b and MBP-Oas1a at different concentrations 
below 200 ng were incubated with (+) 3′ UA Probe #1.  MBP-Oas1b could bind to this 
RNA probe at concentrations below 10 ng of protein (Fig. 11), while RNA binding 
activity was not detected at 10 ng with MBP-Oas1a (Fig. 12).  MBP-Oas1btr at 
concentrations of 10 to 100 ng did not exhibit any binding to (+) 3′ UA Probe #1 (Fig. 
13).  MBP2* did not exhibit any binding activity at concentrations twice that of the 
highest tested concentrations of MBP-Oas1a and MBP-Oas1b, suggesting that the 
binding of the two Oas1 fusion proteins to (+) 3′ Probe #1, was specific. 
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Figure 11:  Effect of MBP-Oas1b concentration on binding activity to (+) 3′ UA Probe 
#1.  Binding was tested using increasing concentrations of MBP-Oas1b and 2000 cpm of 
(+) 3′ UA Probe #1.  Lane 1:  200 ng of control MBP2*.  Lane 2: 10 ng of MBP-Oas1b.  
Lane 3: 25 ng of MBP-Oas1b. Lane 4: 50 ng of MBP-Oas1b.  Lane 5:  75 ng of MBP-
Oas1b.  Lane 6:  100 ng of MBP-Oas1b.   Lane 7:  200 ng of MBP-Oas1b.  FP:  Free 
probe.  Binding reactions were separated on a 6 % polyacrylamide non-denaturing gel.  
Bands on the dried gel were detected by A.  PhosphorImaging.  B.  Autoradiography. 
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Figure 12:  Effect of MBP-Oas1a concentration on binding activity to (+) 3′ UA Probe 
#1.  Binding was tested using increasing concentrations of MBP-Oas1a and 2000 cpm of 
(+) 3′ UA Probe #1.  Lane 1:  400 ng of control MBP2*.  Lane 2: 10 ng of MBP-Oas1a.  
Lane 3: 25 ng of MBP-Oas1a. Lane 4: 50 ng of MBP-Oas1a.  Lane 5:  75 ng of MBP-
Oas1a.  Lane 6:  100 ng of MBP-Oas1a.   Lane 7:  200 ng of MBP-Oas1a.  Lane 8:  400 
ng of MBP-Oas1a. FP:  Free probe.  Binding reactions were separated on a 6 % 
polyacrylamide non-denaturing gel.  Bands on the dried gel were detected by A.  
PhosphorImaging.  B.  Autoradiography. 
47 
FP                   1          2         3         4         5        6        7
A.
FP                    1           2           3          4      5          6        7
B.
 
Figure 13:  Effect of MBP-Oas1btr concentration on binding activity to (+) 3′ UA Probe 
#1.  Binding was tested using increasing concentrations of MBP-Oas1btr and 2000 cpm 
of (+) 3′ UA Probe #1.  Lane 1:  200 ng of control MBP2*.  Lane 2: 10 ng of MBP-
Oas1btr.  Lane 3: 25 ng of MBP-Oas1btr. Lane 4: 50 ng of MBP-Oas1btr.  Lane 5:  75 
ng of MBP-Oas1btr.  Lane 6:  100 ng of MBP-Oas1btr.   Lane 7:  200 ng of MBP-
Oas1btr.  FP:  Free probe.  Binding reactions were separated on a 6 % polyacrylamide 





The next RNA probe tested was the (+) 3′ Control Probe #2, which encompasses  
nucleotides 10308-10364 of the WNV Eg101 genome.  The (+) 3′ Control Probe #2 is 
located in the 3′ end of the NS5 gene of WNV Eg101 and is also rich in As and Us.  
Although it has a secondary structure that is similar to (+) 3′ UA Probe #1, it does not 
contain uninterrupted single-stranded stretches of As and Us that are as long as those in 
(+) 3′ UA Probe #1.  MBP-Oas1 protein concentrations of 25 ng, 50 ng, and 100 ng were 
used to test the efficiency of binding of this protein to (+) 3′ Control Probe #2 (Fig. 14, 
for MBP-Oas1b and MBP-Oas1a; Fig. 15, for MBP-Oas1b and MBP-Oas1btr).  
MBP-Oas1b but neither MBP-Oas1a nor MBP-Oas1btr exhibited detectable binding to 
the (+) 3′ Control Probe #2.  Notably, the relative binding activity of MBP-Oas1b to this 
RNA probe was similar to that observed with (+) 3′ UA Probe #1.  However, competition 
gel shift assays using these two probes are required to quantify these interactions.  
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Figure 14:  Gel mobility shift assay with (+) 3′ Control Probe #2.  Increasing 
concentrations of MBP-Oas1b or MBP-Oas1a were incubated with (+) 3′ Control Probe 
#2 (1000 cpm).  Lane 1:  Free probe.  Lane 2: 25 ng of MBP-Oas1b.  Lane 3: 50 ng of 
MBP-Oas1b. Lane 4: 100 ng of MBP-Oas1b.  Lane 5:  25 ng of MBP-Oas1a.  Lane 6:  
50 ng of MBP-Oas1a.   Lane 7:  100 ng of MBP-Oas1a.  Lane 8:  100 ng of control 
MBP2*.  Binding reactions were separated on a 6 % polyacrylamide non-denaturing gel.  
Bands on the dried gel were detected by A.  PhosphorImaging.  B.  Autoradiography. 
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Figure 15:  Gel mobility shift assay with (+) 3′ Control Probe #2.  Increasing 
concentrations of MBP-Oas1b or MBP-Oas1btr were incubated with (+) 3′ Control Probe 
#2 (1000 cpm).  Lane 1:  Free probe.  Lane 2: 25 ng of MBP-Oas1b.  Lane 3: 50 ng of 
MBP-Oas1b. Lane 4: 100 ng of MBP-Oas1b.  Lane 5:  25 ng of MBP-Oas1btr.  Lane 6:  
50 ng of MBP-Oas1btr.   Lane 7:  100 ng of MBP-Oas1btr.  Lane 8:  100 ng of control 
MBP2*.  Binding reactions were separated on a 6 % polyacrylamide non-denaturing gel.  
Bands on the dried gel were detected by A.  PhosphorImaging.  B.  Autoradiography. 
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 The last probe tested was (+) 3′ SL Probe #3, which comprised the 3′ terminal 
stem-loop structure of WNV Eg101.  MBP-Oas1 protein at concentrations of 25 ng, 50 
ng, and 100 ng were used to test the binding activity of this protein to (+) 3′ SL Probe #3 
(Fig. 16, for MBP-Oas1b and MBP-Oas1btr; Fig. 17, for MBP-Oas1b and MBP-
Oas1a).  Interestingly, this probe did not bind to any of the Oas1 fusion proteins.  This is 
the longest of the probes used and it contains the longest stretches of dsRNA. 
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Figure 16:  Gel mobility shift assay with (+) 3′ SL Probe #3.  Increasing concentrations 
of MBP-Oas1b or MBP-Oas1btr were incubated with (+) 3′ SL Probe #3 (1000 cpm).  
Lane 1:  Free probe.  Lane 2: 25 ng of MBP-Oas1b.  Lane 3: 50 ng of MBP-Oas1b. 
Lane 4: 100 ng of MBP-Oas1b.  Lane 5:  25 ng of MBP-Oas1btr.  Lane 6:  50 ng of 
MBP-Oas1btr.   Lane 7:  100 ng of MBP-Oas1btr.  Lane 8:  100 ng of control MBP2*.  
Binding reactions were separated on a 6 % polyacrylamide non-denaturing gel.  Bands on 
the dried gel were detected by A.  PhosphorImaging.  B.  Autoradiography. 
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Figure 17:  Gel mobility shift assay with (+) 3′ SL Probe #3.  Increasing concentrations 
of MBP-Oas1b or MBP-Oas1a were incubated with (+) 3′ SL Probe #3 (1000 cpm).  
Lane 1:  Free probe.  Lane 2: 25 ng of MBP-Oas1b.  Lane 3: 50 ng of MBP-Oas1b. 
Lane 4: 100 ng of MBP-Oas1b.  Lane 5:  25 ng of MBP-Oas1a.  Lane 6:  50 ng of 
MBP-Oas1a.   Lane 7:  100 ng of MBP-Oas1a.  Lane 8:  100 ng of control MBP2*.  
Binding reactions were separated on a 6 % polyacrylamide non-denaturing gel.  Bands on 
the dried gel were detected by A.  PhosphorImaging.  B.  Autoradiography. 
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MBP-Oas1b but not MBP-Oas1btr inhibits MBP-Oas1a synthetase activity in vitro 
 Addition of Oas1d, a non-functional synthetase, to Oas1a in 2-5A synthetase 
reactions was recently reported to have an inhibitory effect on the synthetase activity of 
Oas1a (Yan et al., 2005).  To investigate whether the non-functional MBP-Oas1b or 
MBP-Oas1btr could inhibit the synthetase activity of MBP-Oas1a in vitro, 2-5A 
synthetase reactions containing 1 µg of MBP-Oas1a and increasing amounts of either 
MBP-Oas1b or MBP-Oas1btr (0, 0.5X, 1X, 1.5X, and 2X) were analyzed.  The results 
showed that MBP-Oas1b inhibited MBP-Oas1a synthetase activity in a dose-dependant 
manner (Fig. 18, lanes 2-6).  However, this inhibitory effect was not observed after the 
addition of MBP-Oas1btr (Fig. 18, lanes 7-10).  Both ATP and poly (I:C) were in excess 
in these reactions.   
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Figure 18:  Inhibition of MBP-Oas1a synthetase activity.  All reactions contained α32p-
ATP, poly (I:C), and 1 µg of MBP-Oas1a, except Lane 1, which contained no proteins. 
In addition to MBP-Oas1a, reactions also contained: Lanes 2-6: 0, 0.5X, 1X, 1.5X, or 2X 
of MBP-Oas1b, respectively.  Lanes 7-10: 0, 0.5X, 1X, 1.5X, or 2X of MBP-Oas1btr, 





Expression and Purification of murine Oas1 proteins 
 Kakuta et al. (2002), expressed Oas1btr using the pET expression system in a 
previous study.  The expressed Oas1btr protein was not purified; instead crude cell 
extracts were used in their studies of Oas1 synthetase activity and poly (I:C) binding.  In 
the present study, efficient and soluble expression of murine Oas1b was not achieved 
using the pET system.  To investigate whether poor expression levels were a 
characteristic of the Oas1b protein, Oas1btr was next expressed using the pET expression 
system. Expression levels of Oas1btr were not significantly greater than of Oas1b; the 
solubility of Oas1btr was not determined.  Expression of Oas1a was not attempted using 
this system.  It is not clear why the levels of soluble Oas1b/btr were so low when 
expressed using this system.  Oas1a shares 82% amino acid sequence homology with 
Oas1b, with the greatest variability in the C-terminus and the next greatest variability in 
the N-terminus.  The two proteins are most homologous within the central, 
nucleotidyltransferase domain.  Hydrophobicity plots of the amino acid sequences of both 
Oas1a and Oas1b showed that the tail of the Oas1b protein is more hydrophobic than that 
of Oas1a.  The hydrophobic sequence at the C-terminus of Oas1b may have contributed 
to the expression of insoluble protein using the pET expression system. 
Subsequently, the pMAL Protein Fusion and Purification System was used to 
express Oas1a, Oas1b and Oas1btr as MBP-fusion proteins in bacteria.  All 3 of the Oas1 
proteins expressed using the pMAL system were soluble and expressed at levels adequate 
for purification.  However, the observed expression level of MBP-Oas1a was 
significantly higher than that of either MBP-Oas1btr or MBP-Oas1b.  Relative to MBP-
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Oas1b, MBP-Oas1btr was expressed at lower levels.  The purified proteins were 
subsequently used in in vitro 2-5A synthetase assays and in gel shift mobility assays with 
RNA probes from the 3′ end of the WNV genomic RNA. 
 
2′-5′ oligoadenylate synthetase activity 
 Oas1a and Oas1g were previously reported to be functional 2′-5′ oligoadenylate 
synthetases (Kakuta et al., 2002).  In that study, Oas1 proteins in bacterial lysates were 
incubated with poly (I:C)-agarose bead, the bound proteins were then used in a 2-5A 
synthetase activity assay.  Using this technique, variation in activation of the Oas1 
proteins by poly (I:C) could in part be due to differences in the poly (I:C) binding 
activities of the tested proteins.  Bacterial proteins present in the crude cell extracts also 
may compete with Oas1 proteins for binding of poly (I:C), producing results that may be 
unreliable.  Although Oas1btr was tested by Kakuta et al. (2002) and found not to be 
active, it was found to bind poly (I:C).  Full-length Oas1b was not previously tested for 
RNA binding or synthetase activity.  In the present study, neither MBP-Oas1b nor MBP-
Oas1btr showed detectable 2-5A synthetase activity.  Under the same conditions, MBP-
Oas1a produced 2-5A oligomers.   
A previous study showed that enzyme activity was almost completely lost when 
mutations were introduced in the putative active sites of human OAS isozymes (Sarkar et 
al., 2002).  The Oas1b protein contains R90Q and R91Q substitutions in the substrate 
binding acceptor site, and also S203R and K209T substitutions in the substrate binding 
donor site.  Oas1b also has a 4 amino acid deletion in the P-loop which may prevent it 
from folding into a catalytically functional structure.  These mutations predicted that the 
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full-length Oas1b protein would not be an active synthetase.  The results in the present 
study confirmed the prediction that Oas1b is not a functional 2-5A synthetase.   
The production of 2-5A and its subsequent activation of RNase L are important 
components of one of the IFN-induced antiviral pathways in cells.  There is a growing 
amount of evidence that 2-5A synthetases can participate in non-enzymatic cellular 
functions.  For instance, an alternatively spliced product of the human OAS1 gene 
designated 9-2/E17 is an active synthetase.  Interestingly, this isozyme also contains a 
BH3 domain through which it has been reported to interact with Bcl-2 family proteins 
inducing apoptosis (Ghosh et al., 2001), demonstrating that this protein has two mutually 
independent activities, namely, synthesizing 2-5A and promoting apoptosis.  A yeast two-
hybrid system was used to screen a human B cell cDNA library with PRL-R (prolactin 
receptor) and a human OAS1 isoform was reported to interact with PRL-R.  
Overexpression of the human OAS1 decreased the basal activity of both the IRF-1 and β-
casein promoters by 40-60 % via an RNase L-independent mechanism (McAveney et al., 
2000; Zhou et al., 1993).  Overexpression of both PRL and OAS1 decreased IRF-1 
promoter activity by 60% (McAveney et al., 2000).  
 
Inhibition of Oas1a synthetase activity 
Human OAS1 proteins have a CFK motif at their C-terminus which is required 
for tetramerization of these proteins (Ghosh et al., 1997).  Hartmann et al. (2003) reported 
that the porcine OAS1, which is 73 % identical in sequence to human OAS1, crystallized 
as a monomeric protein.  Amino acids important for folding of the porcine OAS1 and the 
mouse Oas1b share an overall identity of 56 % (Hartmann et al., 2003).  The ability of 
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mouse Oas1 proteins to multimerize has not yet been investigated.  The CFK motif is 
conserved in the full-length Oas1b protein, but the Oas1a protein contains a K to I 
substitution in this motif and it is possible that this mutation could affect protein-protein 
interactions facilitated via the CFK motif.  Yan et al. (2005) demonstrated that Oas1a 
synthetase activity was inhibited by addition of Oas1d in vitro, presumably via direct 
protein-protein interactions.  Once activated by dsRNA, Oas1a is ubiquitously expressed 
in multiple tissues.  The ovary-specific expression pattern of Oas1d, suggests a role for 
this protein during oogenesis and/or embryogenesis.  Oas1c and Oas1e, which are other 
non-functional synthetases, are also abundantly expressed in oocytes.  Upon viral 
infection, the Oas1a-mediated IFN response is ubiquitous.  The authors suggest that this 
inhibitory effect of Oas1d could serve a protective function by blocking or down-
regulating the IFN/OAS/RNase L RNA degradation pathway to prevent the loss of 
oocytes during acute viral infection; thus maintaining female fertility.  However, Oas1d 
may have an RNase L independent function in regulating development. 
In the present study, MBP-Oas1b was shown to inhibit MBP-Oas1a synthetase 
activity.  The resistant phenotype is characterized by a 100-fold or more decrease in the 
amount of intracellular viral RNA; thus, any inhibition of Oas1a synthetase activity by 
Oas1b in vivo would be inconsistent with the theory that a mechanism involving RNase L 
mediated viral RNA degradation via 2-5A synthetase activity confers flavivirus 
resistance.  In support of the validity of the interaction between MBP-Oas1a and MBP-
Oas1b, the inhibitory effect was not observed after the addition of MBP-Oas1btr (Fig 18, 
lanes 7-10).  Oas1btr has a C-terminal truncation that may prevent protein-protein 
interactions.  The results of the present study showed that MBP-Oas1b is not a functional 
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synthetase and that it can inhibit the 2-5A synthetase activity of Oas1a.  These data 
suggest that Oas1b confers the flavivirus resistance phenotype through a mechanism that 
is independent of the RNase L-RNA degradation pathway.   
 
RNA binding activity 
Poly (I:C) has been used as the standard activator of IFN and OAS for decades 
(Minks et al., 1979); however, it is a synthetic RNA that is not present in cells.  Poly (I:C) 
consists of double strands formed by homopolymers that are not interrupted by single-
stranded bulges or loops.  Cellular RNAs are single-stranded but can form secondary and 
tertiary interactions.  Longer synthetic dsRNAs (40 to 110 bp) have been reported to 
activate 2-5A synthetases more efficiently than shorter dsRNAs (25 bp) at subsaturating 
concentrations of ~100 nM (Desai and Sen, 1997).  Full activation by the short dsRNAs 
is only observed at saturating concentrations (Sarkar et al., 1999).  Han and Barton 
(2002) reported a threshold concentration of 20 nM of HCV mRNA for activation of 
human 2-5A synthetase.  In comparison to the standard poly (I:C) concentration used for 
activation of 2-5A synthetases (50 µg/ml), full activation of human 2-5A synthetase 
activity in HeLa cell extracts by HCV  genome RNA (~9.6 kb) required a concentration 
of ~350 µg/ml.  These observations suggest that although a high level of activation of 2-
5A synthetases is achieved by relatively low concentrations of poly (I:C), the 
physiological levels of viral RNAs in infected cells would not be sufficient to achieve 
significant levels of RNase L activation until late in the infection cycle.  The effect of the 
flavivirus resistance phenotype on viral RNA can be observed as early as 2 hrs after 
infection (Yan and Brinton, unpublished data). 
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Kakuta et al. (2002) reported RNA binding activity of Oas1a and Oas1btr using 
poly (I:C)-agarose beads that were incubated with crude cell lysates prepared from 
bacterial cultures expressing Oas1 proteins.  The bound Oas1 proteins were detected 
using anti-His antibody.  All Oas1 proteins tested in that study exhibited binding to poly 
(I:C).  However, some of the binding activity observed could have been due to other 
bacterial proteins, similar in size to the Oas1 proteins and with His-rich regions, which 
may non-specifically bind.  The anti-His antibody can detect cell proteins rich in His 
residues, such as heat-shock proteins.  Because poly (I:C)-agarose beads are no longer 
commercially available and because attempts to make poly (I:C)-agarose beads in the lab 
failed, poly (I:C)-agarose beads were not used to study Oas1 protein-RNA interactions.  
However, poly (I:C) was used to activate Oas1 synthetase activity.  RNA probes 
synthesized from the 3′ end of WNV Eg101 were used to compare the RNA binding 
activity of the Oas1 proteins. 
Among flaviviruses, the 3′ terminal region of the genome RNAs contains 
conserved structures, despite exhibiting little sequence homology.  Many flavivirus 
genomes contain regions that are rich in As and Us in their 3′ UTR immediately 
following the stop codon.  The sequences within these regions may be targets for RNase 
L digestion which occurs at UA and UU dinucleotides.  The 3′ terminal stem-loop that is 
the most highly conserved of the 3′ UTR structures among divergent flaviviruses.  
According to secondary structure predictions based on the whole genome fold, the next 
two proximal stem-loop structures with relatively high probability of forming are located 
at the end of the NS5 gene and in the 5′ region of the 3′ UTR.  The RNA binding 
activities of the various MBP-Oas1 fusion proteins to the three WNV 3′ probes was 
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compared.  Both MBP-Oas1a and MBP-Oas1a showed binding to the AU-rich probes 
located at or near the 5′ end of the 3′ UTR.  Neither MBP-Oas1a nor MBP-Oas1b bound 
to the 3′ stem-loop at the protein concentrations tested.  In contrast to the previous results 
that demonstrated binding of Oas1btr to poly (I:C)-agarose (Kakuta et al., 2002), MBP-
Oas1btr did not bind to any of the probes tested.  Results presented in this study, 
demonstrate that MBP-Oas1b and MBP-Oas1a exhibit RNA binding activity to regions 
of the 3′ end of the WNV genomic RNA.  To our knowledge this is the first report of 
specific interactions between a 2′-5′ oligoadenylate synthetase and particular regions of a 
viral genome.  These results suggest that if the flavivirus resistance mechanism mediated 
by Oas1b involves viral RNA-protein interactions and/or protein-protein interactions, 
then the truncated form of Oas1b expressed in susceptible cells would not be able to 
mediate these interactions. 
 
Future directions 
 The 2-5A synthetase activity of three mouse Oas1 proteins was tested in the 
present study using poly (I:C).  MBP-Oas1a was the only functional synthetase.  In future 
studies, the ability of different regions of the WNV RNA to activate Oas1 proteins will be 
investigated.  
 Results from the present study suggest that the structures of the human and 
porcine OAS1 proteins may differ from that of the mouse Oas1 proteins.  Crystallization 
studies and subsequent comparison of the crystal structures of the porcine OAS1 protein 
and the mouse Oas1a or Oas1b proteins will require the production of large amounts of 
Oas1 proteins and for this, in vitro transcription/translation systems or the 
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baculovirus/insect expression system will be used.  As one means of detecting cellular or 
viral proteins that may interact with Oas1b, recombinant MBP-Oas1b fusion protein will 
be used in in vitro pull-down and co-immunoprecipitation assays with extracts from 
C3H.PRI.Flvr (resistant) or C3H/He (susceptible) cells.  Recombinant MBP-Oas1b 
protein will also be used for in vivo studies of interacting partners using the Chariot 
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